ReviewFrontiers in immunology2026
Liver transplantation-related osteoporosis and fragility fractures: pathogenic pathways, risk stratification and novel targeted therapy advances.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplantation (LT) serves as the definitive treatment for end-stage liver disease. Yet, osteoporosis (OP) and fragility fractures remain frequently overlooked skeletal complications that may impair the long-term prognosis of recipients. This review systematically summarizes recent evidence regarding epidemiological characteristics, multifactorial pathogenic pathways, risk stratification approaches, and advances in targeted interventions for LT-related bone disorders. Skeletal damage distributes across pre-transplant waiting, early post-transplant acute and long-term chronic phases; rapid bone loss and elevated fracture risk potentially peak within the first year after LT. Pre-transplant hepatic dysfunction-induced malnutrition, endocrine disturbance, and chronic inflammation lay baseline skeletal impairment. In contrast, perioperative high-dose glucocorticoids, calcineurin inhibitor toxicity, surgical denervation, and ischemia-reperfusion injury may jointly drive substantial elevation of bone turnover in the early post-transplant stage. Long-term cortical bone repair deficiency could be attributed to persistent secondary hyperparathyroidism, post-transplant diabetes, and genetic susceptibility. Dual-energy X-ray absorptiometry remains the standard bone mineral density diagnostic tool, while vertebral computed tomography attenuation value and simplified clinical scoring systems support auxiliary risk stratification for skeletal health. Generalized nutritional and lifestyle interventions combined with anti-resorptive agents form mainstream management schemes; DKK-1/Wnt/β-catenin pathway-targeted therapy shows potential as a novel intervention direction. Pediatric LT recipients feature unique bone maturation characteristics that require age-specific evaluation criteria, though unified standardized protocols remain insufficient. Current clinical practice suffers from inadequate bone health screening and pharmacotherapy coverage. Further prospective trials are warranted to validate optimized stratified screening algorithms and individualized targeted regimens for high-risk LT populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.